about
Evolution of proviral gp120 over the first year of HIV-1 subtype C infectionHIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmissionEffect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral-naive, HIV-infected adults in Botswana: a randomized clinical trialTiming constraints of in vivo gag mutations during primary HIV-1 subtype C infectionTemporal reduction of HIV type 1 viral load in breast milk by single-dose nevirapine during prevention of MTCTTransmission of single and multiple viral variants in primary HIV-1 subtype C infection.Vitamin D insufficiency in HIV-infected pregnant women receiving antiretroviral therapy is not associated with morbidity, mortality or growth impairment in their uninfected infants in Botswana.Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in BotswanaPhylogenetic relatedness of circulating HIV-1C variants in Mochudi, BotswanaAn augmented SMS intervention to improve access to antenatal CD4 testing and ART initiation in HIV-infected pregnant women: a cluster randomized trialIncreased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancyPrevalence of human papillomavirus genotypes and associated cervical squamous intraepithelial lesions in HIV-infected women in Botswana.Highly active antiretroviral therapy versus zidovudine for prevention of mother-to-child transmission in a programmatic setting, Botswana.Evolutionary gamut of in vivo Gag substitutions during early HIV-1 subtype C infection.Estimated age and gender profile of individuals missed by a home-based HIV testing and counselling campaign in a Botswana community.Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering.Validation of A Point-of-Care Lactate Device For Screening At-Risk Adults Receiving Combination Antiretroviral Therapy In BotswanaAbacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women.Recruitment, Follow-Up and Characteristics of HIV Infected Adults who Use Illicit Drugs in Southern Africa.Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection.Point-of-Care Cepheid Xpert HIV-1 Viral Load Test in Rural African Communities Is Feasible and Reliable.Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based surveyHIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana.Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind, randomised, placebo-controlled trial.Linear Growth Faltering Among HIV-Exposed Uninfected Children.Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial.Response to antiretroviral therapy after a single, peripartum dose of nevirapine.Correction for Novitsky et al., Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering.Cotrimoxazole prophylaxis was associated with enteric commensal bacterial resistance among HIV-exposed infants in a randomized controlled trial, Botswana.The effect of micronutrient supplementation on active TB incidence early in HIV infection in Botswana.HIV Exposure and Formula Feeding Predict Under-2 Mortality in HIV-Uninfected Children, BotswanaCross-sectional estimates revealed high HIV incidence in Botswana rural communities in the era of successful ART scale-up in 2013-2015Increased Risk of Preterm Delivery Among HIV-Infected Women Randomized to Protease Versus Nucleoside Reverse Transcriptase Inhibitor–Based HAART During PregnancyLow rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in BotswanaLow rates of NRTI and NNRTI drug resistance among participants in the Botswana combination prevention program (BCPP) trialLack of Virological Suppression Among Young HIV-Positive Adults in Botswana
P50
Q24653373-940A6C8C-7DB1-4A9E-AA16-6498146EEAF0Q28473637-A39DE2E3-C87F-405B-BF15-713DE6E79292Q30624220-06797E03-49B6-49E5-BA30-489292352F8DQ33515034-2E1AEA1B-27E9-4FD6-AA7E-EB56AD0FFC62Q33686897-AD241AF8-F132-424A-8428-5765184B8EBFQ33849796-97DB5667-D2A2-4783-B155-01DB63CC64E8Q34437771-1083495C-5575-492A-AE55-435171F8619BQ34500824-5CF937E3-EE1A-4128-B4EA-C74F36DE5011Q35069391-94083062-FDE8-4F12-8501-59A220AC3456Q35101541-923032D2-E4B0-4F31-B6EA-BD57A507C26DQ35129403-3A184E11-846E-4E10-A5FA-960148D51C98Q35164233-D707B22F-A96F-4BA0-8DE2-46AAA13158B6Q35386228-E1A67238-374F-4087-8C30-A4A56D101632Q35535663-273D48A9-2C41-4517-8680-58536CD47062Q35668867-6E621B16-FC3F-4B93-9F39-7E7A6D86F79CQ35868716-CBAD4738-F5C7-4258-9526-B6C20D08BB59Q36329990-47892CE9-8EFC-4B8E-8240-58EEFD9488A0Q36404094-15AF2E70-6F92-47CE-BDA4-21C519A6E1C5Q36539842-9BA21042-3B94-4EB5-8567-D8C7B7A6DACDQ37240053-2479C0C2-FF91-47E6-A080-F96B9F0495F7Q37434357-A6493707-A110-4738-8406-887C6023330CQ37487542-058F1505-F5BD-42A9-9564-4625A0E466BCQ37703445-240540E5-182D-4887-9FFF-A528A9FB7B64Q38404645-69698F0B-6C1E-4926-A4B8-4D9E7744017DQ38843857-05CFC9AF-AD3E-4B3A-AA90-95DD687DA600Q40698604-BFD9885A-3F8C-4B5A-A865-27007A1E9671Q40799084-798D91D7-F698-4769-81FE-717E4A34C5F1Q40799526-D282F9BC-51DC-4C2A-A7CE-8AC4880F90BDQ42931814-6CC8E47B-7A41-4B72-B481-5C8F51818E58Q46265061-9E0D0B2D-0B3B-41E9-8329-57BD7ACE42F2Q47159987-C37982D4-0991-4E5C-ABED-C58A4095AA5AQ57476292-B559387B-9A17-4343-8BD0-AFB7360B00CCQ57794223-7B1BD41B-92D0-4184-9BE0-FFA75A2B8BB8Q59390910-EFDC8F50-C73C-4522-8700-58C97475496CQ64126110-AA174284-0116-446A-8FEF-DAF9341F91D5Q64130517-3FEC4534-7BC8-4F1B-979F-99DCCF764765Q64137712-55254006-F644-47A0-BB7E-377596E3E6A6
P50
name
Erik van Widenfelt
@en
type
label
Erik van Widenfelt
@en
prefLabel
Erik van Widenfelt
@en